Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2026Blood Cancer Discovery

Hattrick against Lymphoma with Trispecific CAR T Cells

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates trispecific CAR T cells for lymphoma, suggesting impact of T-cell fitness on outcomes.

Key Points

  • The study aims to evaluate the efficacy and safety of trispecific CAR T cells in lymphoma treatment.
  • Clinical evaluation of rapidly manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
  • Correlative analyses assessing baseline T-cell fitness and post-infusion functional states.
  • Efficacy signal observed in lymphoma treatment with the trispecific CAR T cells.
  • Favorable safety profile supports further investigation.
  • Baseline T-cell fitness and early post-infusion functional states are important outcome determinants.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a7d75d82b0e0cff3f63eaa3https://doi.org/10.1158/2643-3230.bcd-26-0257
View Full Paper
Ask AI
Bookmark
Share